Approval of targeted therapies first line for prostate cancer ‘will ease COVID-19 pressures’ 06 May 2020 The Institute of Cancer Research, London, has broadly welcomed the approval of targeted hormone therapies enzalutamide and abiraterone as first-line NHS treatments for men with advanced prostate cancer. Find out more Show/Hide
ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men with advanced prostate cancer 30 Sep 2019 A drug used for breast and ovarian cancer is more effective than modern targeted hormone treatments at slowing progression and improving survival in some men with advanced prostate cancer, phase III clinical trial findings reveal. Find out more Show/Hide
ESMO 2019: Modern chemotherapy drug better than second targeted hormone therapy against resistant prostate cancer 30 Sep 2019 A modern chemotherapy drug is more effective for men with advanced prostate cancer than a second targeted hormone therapy in patients who have stopped responding to treatment, a major clinical trial shows. Find out more Show/Hide
Protein found more in advanced prostate cancer could be key to preventing drug resistance 08 Jan 2019
Cancer researchers, family and friends gather to celebrate award of Queen’s Regius Professorship to Professor Johann de Bono 20 Sep 2018